Molecular structure of Olmesartan acid, CAS Number: 144689-24-7
Olmesartan acid (CAS 144689-24-7)
See product citations (7)
Alternate Names:
5-(2-hydroxypropan-2-yl)-2-propyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylic acid
Application:
Olmesartan acid is an angiotensin II (AT1) receptor antagonist
CAS Number:
144689-24-7
Purity:
≥98%
Molecular Weight:
446.51
Molecular Formula:
C24H26N6O3
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Olmesartan Acid is an angiotensin II receptor antagonist that prevents the binding of angiotensin II, thus preventing vasoconstriction. In vitro studies have demonstrated the robust and specific binding of olmesartan to the AT1 receptor, showcasing its potency as an olmesartan. Furthermore, this compound exhibits an extended duration of activity, with a half-life of approximately 24 hours.
Olmesartan acid (CAS 144689-24-7) References
- Impact of Olmesartan Medoxomil on Amiodarone-Induced Pulmonary Toxicity in Rats: Focus on Transforming Growth Factor-ß1. | Sharaf El-Din, AA. and Abd Allah, OM. 2016. Basic Clin Pharmacol Toxicol. 119: 58-67. PMID: 26781185
- Olmesartan Inhibits Cardiac Hypertrophy in Mice Overexpressing Renin Independently of Blood Pressure: Its Beneficial Effects on ACE2/Ang(1-7)/Mas Axis and NADPH Oxidase Expression. | Tanno, T., et al. 2016. J Cardiovasc Pharmacol. 67: 503-9. PMID: 26886190
- Sprue-like enteropathy linked to olmesartan. | Campos Ruiz, A., et al. 2016. Rev Esp Enferm Dig. 108: 292-3. PMID: 26925975
- Olmesartan-associated sprue-like enteropathy: a systematic review with emphasis on histopathology. | Burbure, N., et al. 2016. Hum Pathol. 50: 127-34. PMID: 26997446
- Olmesartan-associated sprue-like enteropathy: know your enemy. | Ianiro, G., et al. 2016. Scand J Gastroenterol. 51: 891. PMID: 27001009
- Design, formulation and optimization of novel soft nano-carriers for transdermal olmesartan medoxomil delivery: In vitro characterization and in vivo pharmacokinetic assessment. | Kamran, M., et al. 2016. Int J Pharm. 505: 147-58. PMID: 27005906
- Retraction: 'Effects of an olmesartan/amlodipine fixed dose on blood pressure control, some adipocytokines and interleukins levels compared with olmesartan or amlodipine monotherapies' by G. Derosa, A. F. G. Cicero, A. Carbone, F. Querci, E. Fogari, A. D'Angelo and P. Maffioli. | . 2016. J Clin Pharm Ther. 41: 237. PMID: 27059120
- Olmesartan-induced enteropathy associated with cutaneous lesions. | Hammoudi, N., et al. 2016. Clin Case Rep. 4: 379-82. PMID: 27099732
- [Enteropathy due to olmesartan]. | Ould Sidi Mohamed, M. and Colardelle, P. 2016. Ann Cardiol Angeiol (Paris). 65: 286-9. PMID: 27129872
- Olmesartan: sprue-like enteropathy. | . 2016. Prescrire Int. 25: 130-1. PMID: 27280200
- Novel Solid Self-Nanoemulsifying Drug Delivery System (S-SNEDDS) for Oral Delivery of Olmesartan Medoxomil: Design, Formulation, Pharmacokinetic and Bioavailability Evaluation. | Nasr, A., et al. 2016. Pharmaceutics. 8: PMID: 27355963
- Transport Kinetics, Selective Inhibition, and Successful Prediction of In Vivo Inhibition of Rat Hepatic Organic Anion Transporting Polypeptides. | Ishida, K., et al. 2018. Drug Metab Dispos. 46: 1251-1258. PMID: 29891589
- LC and NMR Studies for Identification and Characterization of Degradation Byproducts of Olmesartan Acid, Elucidation of Their Degradation Pathway and Ecotoxicity Assessment. | Luongo, G., et al. 2021. Molecules. 26: PMID: 33809869
- Nonpeptide angiotensin II receptor antagonists: synthesis, biological activities, and structure-activity relationships of imidazole-5-carboxylic acids bearing alkyl, alkenyl, and hydroxyalkyl substituents at the 4-position and their related compounds. | Yanagisawa, H., et al. 1996. J Med Chem. 39: 323-38. PMID: 8568823
- Blood pressure and endocrine effects of single doses of CS-866, a novel angiotensin II antagonist, in salt-restricted hypertensive patients. | Püchler, K., et al. 1997. J Hypertens. 15: 1809-12. PMID: 9488244
Inhibitor of:
ANG III, Angiotensin, Angiotensin Receptor, Oatp4, Olfr770, Olfr771, OR5K1, V1RA5, V1RA6, and Vmn2r98.Activator of:
AT1a.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Olmesartan acid, 10 mg | sc-219481 | 10 mg | $156.00 | |||
Olmesartan acid, 500 mg | sc-219481A | 500 mg | $208.00 | |||
Olmesartan acid, 1 g | sc-219481B | 1 g | $333.00 | |||
Olmesartan acid, 2 g | sc-219481C | 2 g | $533.00 | |||
Olmesartan acid, 5 g | sc-219481D | 5 g | $1072.00 |